| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
-Interferon Production in Human Peripheral Blood Mononuclear Cells1
Divisions of Infectious Diseases [T. C. C.], Hematology [L. M. S.], and Immunology [S. G.], Department of Medicine, University of California Irvine, Orange, California 92668; Division of Infectious Diseases, Department of Medicine, Marshall University, Huntington, West Virginia 25701 [G. J. G.]; and American Red Cross, Orange County California Division, Santa Ana, California 92705 [H. S. K.]
Since
-interferon (IFN-
) is a potent immunomodulator and patients receiving certain antineoplastic agents are at risk of unusual infections, we have determined the effect of certain antineoplastic agents on IFN-
production. Induction of peripheral blood mononuclear cells from normal donors in the presence and absence of various antineoplastic agents was achieved using phytohemagglutinin (8 µg/ml). Supermatants were then separated by centrifugation, dialyzed, and assayed for interferon. Cell viability was always greater than 85% with or without the presence of drugs. Hydrocortisone was found to eliminate IFN-
production if added within 24 hr after the phytohemagglutinin. The suppression of IFN-
production occurred with hydrocortisone concentrations as low as 0.65 µg/ml, was associated with a diminished proliferative response to the lectin, and occurred with other interferon inducers including staphylococcal enterotoxin A.
Adriamycin (0.4 µg/ml) and vincristine (0.08 µg/ml) also diminished IFN-
production, but only if the peripheral blood mononuclear cells were pretreated with the drugs.
Methotrexate, 5-fluorouracil, and 6-mercaptopurine failed to influence the yield of IFN-
.
These results are significantly different from experiments previously reported using
- and ß-interferons and suggest an important mechanism by which these drugs can produce immunosuppression.
1 This research was supported by a grant from the KROC Foundation and a grant from the Alaska Cancer Research Telethon through the American Cancer Society.
2 To whom requests for reprints should be addressed, at Department of Medicine, University of California Irvine Medical Center, 101 City Drive South, Orange, CA 92668.
Received 4/ 9/84. Accepted 7/31/84.
This article has been cited by other articles:
![]() |
T. Uwatoku, H. Shimokawa, K. Abe, Y. Matsumoto, T. Hattori, K. Oi, T. Matsuda, K. Kataoka, and A. Takeshita Application of Nanoparticle Technology for the Prevention of Restenosis After Balloon Injury in Rats Circ. Res., April 18, 2003; 92 (7): e62 - e69. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |